Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.ZEBOV and MVA-BN-Filo for Ebola Prevention
NCT02598388Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 6
01
Overview
A Phase 2 trial of zabdeno, Mvabea in Ebola virus disease (EVD), sponsored by Janssen Pharmaceutical. Started Dec 2015; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02598388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598388.